Bivin & Associates’s Gossamer Bio GOSS Stock Holding History

Bivin & Associates’s Portfolio GOSS Stock Details GOSS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-70	Closed	-$1K	–	377
2021 Q4	$1K	Buy	+70	New	+$831	﹤0.01%	313

Other funds holding GOSS

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bivin & Associates's GOSS Position: Q1 2022 in Review

Bivin & Associates sold out of Gossamer Bio (GOSS) in Q1 2022, closing a stake of 70 shares — an estimated $1K sold.

Bivin & Associates first reported a position in GOSS in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 141 funds tracked by Wall St. Rank hold GOSS as of Q1 2022.

Bivin & Associates reported no remaining Gossamer Bio position as of Q1 2022 after selling out during the quarter.
Bivin & Associates sold 70 Gossamer Bio shares in Q1 2022, an estimated $1K.
Bivin & Associates first reported a position in Gossamer Bio in Q4 2021 and held it in 1 quarter.
Bivin & Associates's Gossamer Bio position peaked at $1K in Q4 2021.
141 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2022.

Based on Bivin & Associates's 13F filing for Q1 2022, filed 6 May 2022.